family with sequence similarity 89 member BGenealiases: LRAP25 · MTVR · MTVR1
Q-omics provides the consensus-scored FAM89B profile across patient tissues and cancer cell-line models. FAM89B expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM89B is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, FAM89B RNA expression shows 18,679 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FAM89B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM89B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM89B survival associations across molecular data types. FAM89B RNA expression shows survival associations in the most cancer types (20), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM89B RNA expression–survival associations across cancer types. High FAM89B expression shows unfavorable associations in ACC, LIHC, LAML and KICH, but favorable associations in LUAD and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FAM89B RNA expression.
This table summarizes FAM89B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM89B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM89B shows higher tumor expression in KIRC, HNSC, KIRP, THCA, LIHC and LUSC. The KIRC box plot shows higher FAM89B RNA expression in tumor versus normal tissue (log2 FC = +1.091, t-test p < 0.001).
This table shows molecular features associated with FAM89B in patient tissues and cancer cell lines. In patient samples, FAM89B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM89B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
